About the company
Driven by a deep commitment to life, a dedicated team of patients and scientists is shaping a future of boundless motion and freedom. With relentless passion and innovation, they push the limits of what is possible, pioneering groundbreaking therapeutics for chronic degenerative diseases. Their mission is to develop first-in-class technology with transformative potential, addressing critical unmet needs in rheumatology and orthopedics. United by a shared vision, they are paving the way for the next generation of healthcare solutions.
Why invest?
Osteoarthritis affects 650 million people worldwide, causing pain, inflammation, and reduced mobility. A groundbreaking injectable therapeutic device has been developed to treat the root cause of the disease rather than just alleviating symptoms. This first-in-class solution offers a rapid market entry with strong commercial potential, positioning it as a game-changer in osteoarthritis treatment.
The device has demonstrated clear superiority over existing treatments, including hyaluronic acid, with clinical trials showing an 89% response rate and long-term efficacy. With a well-defined regulatory pathway and high unmet medical need, this investment presents a significant financial opportunity.
A unique investment opportunity
The device uses a 3-stage mechanotransductive action to trigger immune response and regenerative processes for lasting clinical benefits. Safety was confirmed in pre-clinical rodent studies, and trials with 81 horses showed excellent results, keeping them lameness-free for over a year.
Regulatory approval is in progress in Europe and the U.S. The EU Phase I-II study with 100 patients will assess safety and tolerability, with market entry expected by mid-2027. In the U.S., Phase III trials with 200 patients and a superiority study with 300 patients are planned for 2026-2027. With EU approval in 2027 and U.S. entry in 2028, this breakthrough treatment is set to dominate the osteoarthritis market and drive revenue growth.
The investment
The company is seeking €1M through a convertible loan agreement (CLA).
Interested?
Get in touch to explore investment opportunities in this medical biotechnology.